Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Rhea-AI Summary
Candel Therapeutics (NASDAQ: CADL) will present updated, extended-follow-up data from its randomized Phase 3 trial of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer at the AUA 2026 Annual Meeting in Washington, D.C., on May 15, 2026.
The oral plenary will report accumulating benefit for patients treated with CAN-2409 plus prodrug combined with standard external beam radiation; full abstracts and presentation details will be released at the event and posted by the company afterward.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CADL
On the day this news was published, CADL gained 3.85%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.1% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $14M to the company's valuation, bringing the market cap to $377.21M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer action is mixed: CAPR is up about 10.95%, NMRA up 3.31%, while ANNX is down 4.46%. Scanner data flags no coordinated sector move around this clinical-trial update.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Sep 29 | Phase 3 data | Positive | -2.5% | Positive Phase 3 CAN-2409 prostate cancer data presented at ASTRO 2025. |
| May 22 | Phase 3 results | Positive | +0.2% | ASCO 2025 Phase 3 CAN-2409 data showing reduced recurrence or death risk. |
| Apr 23 | ASCO presentation | Positive | +5.0% | Announcement of upcoming ASCO oral presentation of Phase 3 CAN-2409 data. |
| Apr 01 | Phase 1b data | Positive | -1.4% | Publication of Phase 1b CAN-2409 plus nivolumab data in high-grade glioma. |
| Mar 26 | Phase 2a NSCLC data | Positive | -7.3% | Phase 2a CAN-2409 NSCLC survival and abscopal effect results released. |
Positive CAN-2409 clinical updates have often seen modest or even negative next-day moves, suggesting limited immediate upside reaction despite favorable data.
Over the past year, Candel has repeatedly highlighted CAN‑2409’s clinical profile across indications. Localized prostate cancer Phase 3 data at ASCO and ASTRO in 2025 showed meaningful disease‑free survival and response benefits. Additional Phase 1b glioma and Phase 2a NSCLC data underscored broader immunotherapy potential. Despite generally positive results, same‑day or next‑day stock moves around these clinical trial disclosures have been mixed, with several negative reactions, framing today’s AUA presentation notice within a pattern of cautious market reception.
Historical Comparison
Past clinical trial headlines for CAN-2409 led to an average move of -1.21%, showing that strong data have historically produced only modest, often slightly negative, price reactions.
Clinical news traces CAN-2409 from Phase 3 success in localized prostate cancer at ASCO/ASTRO 2025 to Phase 1b glioma and Phase 2a NSCLC signals, illustrating a broad oncology development program feeding into today’s extended Phase 3 follow-up update.
Regulatory & Risk Context
An effective Form S-3 shelf filed on 2025-08-14 allows Candel to offer up to $300,000,000 of securities, including up to $50,000,000 of common stock via an at-the-market program with Jefferies. Two 424B5 takedowns in February 2026 indicate active use of this capital-raising capacity ahead of potential CAN-2409 commercialization.
Market Pulse Summary
This announcement highlights that CAN‑2409’s Phase 3 prostate cancer data earned a plenary slot in the AUA 2026 Practice‑changing, Paradigm‑shifting session, underscoring perceived clinical relevance. It follows prior positive Phase 3 readouts and reinforces Candel’s focus on intermediate‑ to high‑risk localized disease. Investors may watch for full AUA data, progress toward the planned Q4 2026 BLA submission, and how extended follow‑up shapes views on durability and safety.
Key Terms
randomized phase 3 trial medical
external beam radiation (EBRT) medical
prodrug medical
AI-generated analysis. Not financial advice.
NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session, as part of the American Urological Association (AUA) 2026 Annual Meeting Plenary Program being held in Washington D.C. from May 15-18, 2026. The presentation will feature new data from the Company’s phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with intermediate- to high-risk localized prostate cancer.
Presentation Details:
Aglatimagene – Localized Prostate Cancer
- Abstract Title: Extended follow-up shows accumulating benefit for patients treated with CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) in men with localized prostate cancer: update from PrTK03 randomized phase 3 clinical trial
- Presentation Type: Plenary
- Presenter: Mark G. Garzotto, M.D., Professor of Urology and Radiation Medicine, Oregon Health & Science University, Chief, Urology Section, Portland VA Medical Center
- Session Title: P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology
- Session Date/Time: Friday, May 15, 2026; 11:30 AM - 11:40 AM ET
- Location: Hall D, Walter E. Washington Convention Center, Washington, D.C.
Full abstracts will be released by AUA on date and time of presentation. Details from the presentation will be available following the event on the Candel website at https://www.candeltx.com/media/.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene or CAN-2409) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.
Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat, solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
